JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

AnaptysBio Inc

Chiusa

SettoreSettore sanitario

34.96 3.31

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.6

Massimo

35.04

Metriche Chiave

By Trading Economics

Entrata

699K

-39M

Vendite

-5.5M

22M

Margine di Profitto

-173.517

Dipendenti

136

EBITDA

9.2M

-18M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+75.02% upside

Dividendi

By Dow Jones

Utili prossimi

3 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

275M

987M

Apertura precedente

31.65

Chiusura precedente

34.96

Notizie sul Sentiment di mercato

By Acuity

50%

50%

147 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

AnaptysBio Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 ott 2025, 18:41 UTC

Utili

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 ott 2025, 18:31 UTC

Utili

Correction to Procter & Gamble to Focus on Innovation

24 ott 2025, 16:25 UTC

I principali Market Mover

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

24 ott 2025, 21:24 UTC

Discorsi di Mercato

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 ott 2025, 21:07 UTC

Utili

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 ott 2025, 20:58 UTC

Utili

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 ott 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 20:40 UTC

Utili

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 ott 2025, 20:24 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:23 UTC

Utili

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 ott 2025, 20:13 UTC

Utili

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 20:07 UTC

Discorsi di Mercato

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 ott 2025, 19:40 UTC

Discorsi di Mercato

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 ott 2025, 19:35 UTC

Discorsi di Mercato

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 ott 2025, 19:33 UTC

Utili

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 ott 2025, 19:29 UTC

Discorsi di Mercato

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 ott 2025, 18:52 UTC

Utili

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:41 UTC

Utili

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 ott 2025, 18:03 UTC

Utili

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 ott 2025, 18:02 UTC

Utili

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 ott 2025, 18:00 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 ott 2025, 16:57 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 ott 2025, 16:54 UTC

Discorsi di Mercato

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 ott 2025, 16:44 UTC

Discorsi di Mercato
Utili

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 ott 2025, 16:39 UTC

Discorsi di Mercato
Utili

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 ott 2025, 16:33 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:23 UTC

Utili

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 ott 2025, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

24 ott 2025, 16:07 UTC

Utili

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Confronto tra pari

Modifica del prezzo

AnaptysBio Inc Previsione

Obiettivo di Prezzo

By TipRanks

75.02% in crescita

Previsioni per 12 mesi

Media 61.38 USD  75.02%

Alto 90 USD

Basso 20 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AnaptysBio Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

9

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

19.25 / 21.135Supporto e resistenza

A breve termine

Strong Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

147 / 371 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
help-icon Live chat